Q&A with Luca Santarelli: Targeting neuronal connections
Luca Santarelli, head of neuroscience at Roche, explains why he is optimistic that pharmaceutical companies can overcome the obstacles in autism drug development.
Luca Santarelli, head of neuroscience at Roche, explains why he is optimistic that pharmaceutical companies can overcome the obstacles in autism drug development.
A tool designed to detect psychiatric disorders in people with autism may produce more accurate estimates of co-occurring conditions.
A new rat study shows that the precise timing of early valproate exposure, an autism risk factor, can have a big influence on behavior later in development.
Two reviews sketch a road map for understanding and treating autism in low- and middle-income countries.
Studies of autism prevalence should screen a representative sample of all individuals in the population, even those with no indications of the disorder, says epidemiologist Young-Shin Kim.
Multiplayer games can help researchers identify differences in social behavior in people with autism.
Researchers typically use only one ‘cohort,’ a group of about three dozen mice, for a given set of experiments. When others repeat the experiments with a different set of animals, sometimes the results hold up, and sometimes they don’t.
Long-term treatment with antipsychotic drugs and mood stabilizers can change the structure of the brain.
A pilot project highlights how adult stem cells could be used to test and select personalized therapies.
Child psychiatrist and epidemiologist Eric Fombonne digs through the latest report on the prevalence of autism, suggesting reasons for the apparent increase in the disorder’s rates.